$SYK earnings report

Stryker reported third-quarter net sales growth of 7.7% to $6.5 billion, while adjusted EPS increased 10.3% to $3.52 and reported EPS decreased 11.7% to $1.96. AlphAI read Stryker's third quarter of 2026 filing as mixed. 2 quarters are on record below.

third quarter of 2026

AlphAI · Earnings readSYK · third quarter of 2026 · ended September 30, 2026

Stryker reported third-quarter net sales growth of 7.7% to $6.5 billion, while adjusted EPS increased 10.3% to $3.52 and reported EPS decreased 11.7% to $1.96.

→Mixed quarter

Sales and adjusted earnings grew at double-digit and high-single-digit rates, respectively, but management said performance fell short of its expectations and reported operating income, net earnings and diluted EPS declined amid goodwill and other impairments and special charges.

Revenue
$6.52B
7.7 % y/y
MedSurg and Neurotechnology
$3.66B
9.2 % y/y
EPS · non-GAAP
$ 3.52
10.3 % y/y
full year 2026 outlook
organic net sales growth in the range of 6.5% to 7.0%

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net sales, three monthsGAAP$6.52B–7.7 %
Cost of sales, three monthsGAAP$2.27B–3.0 %
Gross profit, three monthsGAAP$4.25B–10.3 %
Gross profit margin, three monthsGAAP65.2 %––
Research, development and engineering expenses, three monthsGAAP$433M–5.6 %
Selling, general and administrative expenses, three monthsGAAP$2.31B–13.1 %
Amortization of intangible assets, three monthsGAAP$175M–(7.4) %
Goodwill and other impairments, three monthsGAAP$293M–nm
Total operating expenses, three monthsGAAP$3.21B–18.3 %
Operating income, three monthsGAAP$1.03B–(8.9) %
Operating income margin, three monthsGAAP15.9 %––
Other income (expense), net, three monthsGAAP−$37M–(65.1) %
Earnings before income taxes, three monthsGAAP$997M–(3.1) %
Income taxes, three monthsGAAP$244M–43.5 %
Net earnings, three monthsGAAP$753M–(12.3) %
Basic EPS, three monthsGAAP$ 1.97–(12.4) %
Diluted EPS, three monthsGAAP$ 1.96–(11.7) %
Adjusted gross profit, three monthsnon-GAAP$4.27B––
Adjusted gross profit margin, three monthsnon-GAAP65.4 %––
Adjusted operating income, three monthsnon-GAAP$1.71B––
Adjusted operating income margin, three monthsnon-GAAP26.2 %–increased 60 bps
Adjusted net earnings, three monthsnon-GAAP$1.36B–10.1 %
Adjusted diluted EPS, three monthsnon-GAAP$ 3.52–10.3 %
Net sales, nine monthsGAAP$19.13B–6.6 %
Gross profit, nine monthsGAAP$12.56B–9.8 %
Gross profit margin, nine monthsGAAP65.6 %––
Operating income, nine monthsGAAP$3.63B–17.6 %
Operating income margin, nine monthsGAAP19.0 %––
Net earnings, nine monthsGAAP$2.77B–15.7 %
Diluted EPS, nine monthsGAAP$ 7.19–16.0 %
Adjusted operating income, nine monthsnon-GAAP$4.78B––
Adjusted operating income margin, nine monthsnon-GAAP25.0 %––
Adjusted net earnings, nine monthsnon-GAAP$3.79B––
Adjusted diluted EPS, nine monthsnon-GAAP$ 9.81––
Net cash provided by operating activities, nine monthsGAAP$3.30B––
Purchases of property, plant and equipment, nine monthsGAAP−$605M––

Segments

SegmentRevenueq/qy/y
MedSurg and NeurotechnologyOrganic net sales increased 9.1% primarily driven by increased unit volume.$3.66B–9.2 %
OrthopaedicsOrganic net sales increased 5.9% from increased unit volume.$2.86B–5.7 %
InstrumentsNot stated.$996M–5.1 %
EndoscopyNot stated.$1.02B–13.9 %
MedicalNot stated.$1.08B–9.7 %
VascularNot stated.$566M–8.0 %
KneesNot stated.$635M–1.1 %
HipsNot stated.$453M–(1.0) %
Trauma and ExtremitiesNot stated.$1.01B–5.3 %
Ortho TechNot stated.$754M–15.8 %
Spinal ImplantsNot stated.$4M–(43.9) %
United StatesNot stated.$4.95B–8.3 %
InternationalNot stated.$1.57B–5.7 %

full year 2026 outlook

  • Revenueorganic net sales growth in the range of 6.5% to 7.0%
  • Noteadjusted net earnings per diluted share to be in the range of $14.80 to $14.90
  • NoteSales guidance includes a modestly positive pricing impact.
  • NoteForeign exchange is expected to have a slightly favorable impact on both sales and adjusted net earnings per diluted share should rates hold near current levels.

Capital returns

  • We repurchased $1.0 billion of our common stock in the third quarter of 2026.
  • Payments of dividends were $ (1,012) million for the nine months 2026.
  • Repurchases of common stock were $ (1,000) million for the nine months 2026.
  • In October 2026 our Board of Directors approved an increase of $3.0 billion to our existing share repurchase program.

What drove it

  • Consolidated organic net sales increased 7.7% primarily driven by increased unit volume.
  • MedSurg and Neurotechnology organic net sales increased 9.1% primarily driven by increased unit volume.
  • Orthopaedics organic net sales increased 5.9% from increased unit volume.
  • Adjusted operating income margin increased 60 bps to 26.2%.

Concerns

  • Management stated that the quarter's good overall performance fell short of its expectations.
  • Reported operating income decreased 8.9% to $ 1,034 million and reported operating income margin was 15.9%, compared with 18.7%.
  • Goodwill and other impairments were $ 293 million, compared with $ 73 million.
  • Reported net earnings decreased 12.3% to $ 753 million and reported diluted EPS decreased 11.7% to $ 1.96.
  • Hips sales declined (1.0) % and Spinal Implants sales declined (43.9) %.

What to watch

  • Full-year organic net sales growth against guidance of 6.5% to 7.0%.
  • Full-year adjusted net earnings per diluted share against guidance of $14.80 to $14.90.
  • The expected modestly positive pricing impact and slightly favorable foreign-exchange impact.
  • The company's expected solid performance in Q4 and good momentum heading into 2027.
  • Further costs associated with structural optimization and other special charges, goodwill and other impairments, medical device regulations, recall-related matters, and regulatory and legal matters.

Balance sheet and cash flow

  • Cash and cash equivalents were $ 3,271 million at September 30, 2026, compared with $ 4,011 million at December 31, 2025.
  • Long-term debt, excluding current maturities, was $ 14,176 million at September 30, 2026, compared with $ 14,859 million at December 31, 2025.
  • Accounts receivable, net, were $ 3,693 million at September 30, 2026, compared with $ 4,039 million at December 31, 2025.
  • Inventories were $ 5,747 million at September 30, 2026, compared with $ 5,310 million at December 31, 2025.
  • Net cash provided by operating activities was $ 3,303 million for the nine months 2026, compared with $ 2,901 million for the nine months 2025.
  • Acquisitions, net of cash acquired, were $ (481) million for the nine months 2026, compared with $ (4,950) million for the nine months 2025.
  • Net cash used in investing activities was $ (1,011) million for the nine months 2026, compared with $ (4,561) million for the nine months 2025.
  • Net cash used in financing activities was $ (2,998) million for the nine months 2026, compared with net cash provided by financing activities of $ 1,206 million for the nine months 2025.
  • Change in cash and cash equivalents was $ (740) million for the nine months 2026, compared with $ (396) million for the nine months 2025.

Analysis

Stryker recorded $ 6,520 million of third-quarter net sales, up 7.7%, with organic net sales also up 7.7%. The release attributes consolidated organic growth primarily to increased unit volume. MedSurg and Neurotechnology was the principal growth contributor, with sales of $ 3,664 million up 9.2% and organic sales growth of 9.1%. Orthopaedics sales were $ 2,856 million, up 5.7%, with 5.9% organic growth. United States sales increased 8.3% to $ 4,950 million, while International sales increased 5.7% to $ 1,570 million.

Reported profitability was affected by charges, despite gross-margin improvement. Gross profit margin was 65.2%, compared with 63.6%, while reported operating income margin declined to 15.9% from 18.7%. Operating income decreased 8.9% to $ 1,034 million, net earnings decreased 12.3% to $ 753 million, and diluted EPS decreased 11.7% to $ 1.96. Goodwill and other impairments were $ 293 million, compared with $ 73 million. The reconciliation also identifies $ 153 million of structural optimization and other special charges in adjusted operating income and $ 293 million of goodwill and other impairments.

Underlying adjusted results improved. Adjusted gross profit margin was 65.4%, compared with 65.0%, and adjusted operating income margin increased 60 bps to 26.2% from 25.6%. Adjusted net earnings increased 10.1% to $ 1,357 million and adjusted diluted EPS increased 10.3% to $ 3.52. Product-level performance was uneven: Endoscopy grew 13.9%, Ortho Tech grew 15.8%, and Vascular grew 8.0%, while Hips declined (1.0) % and Spinal Implants declined (43.9) %.

For the first nine months, net cash provided by operating activities increased to $ 3,303 million from $ 2,901 million. The company used $ (605) million for purchases of property, plant and equipment, paid $ (1,012) million of dividends, and repurchased $ (1,000) million of common stock. Cash and cash equivalents were $ 3,271 million and long-term debt, excluding current maturities, was $ 14,176 million at September 30, 2026. The Board approved an additional $3.0 billion for the existing share repurchase program in October 2026.

Management updated full-year 2026 guidance to organic net sales growth of 6.5% to 7.0% and adjusted net earnings per diluted share of $14.80 to $14.90. The company said its sales guidance includes a modestly positive pricing impact and expects foreign exchange to have a slightly favorable effect on sales and adjusted EPS if rates remain near current levels. Management explicitly said the quarter fell short of expectations, making fourth-quarter delivery against the updated ranges and the stated expectation for solid Q4 performance central to the outlook.

Management, verbatim

We delivered 7.7% organic sales growth and double-digit adjusted earnings growth in the quarter. While, in absolute terms, this reflected good overall performance, it did fall short of our expectations. The underlying fundamentals of the business remain strong, and we expect a solid performance in Q4 and good momentum heading into 2027.

Kevin A. Lobo, Chair and CEO

Not in the filing

stated, not guessed
  • Previous-release outlook and prior-guidance comparisons were not provided.
  • Quarterly operating cash flow was not reported.
  • Free cash flow was not reported.
  • Full-year 2026 GAAP revenue, GAAP EPS, gross margin, operating expenses and tax-rate guidance were not reported.
  • Third-quarter dividend declared per share was not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

second quarter 2026

AlphAI · Earnings readSYK · second quarter 2026 · ended June 30, 2026

STRYKER REPORTS SECOND QUARTER 2026 OPERATING RESULTS

✓Strong quarter

Second-quarter net sales increased 9.4%, organic net sales increased 9.0%, reported diluted EPS increased 44.1%, and adjusted diluted EPS increased 17.9%.

Revenue
$6.59B
9.4% y/y
MedSurg and Neurotechnology
$3.6B
9.7% y/y
EPS · non-GAAP
$3.69
17.9% y/y
full year 2026 outlook
organic net sales growth in the range of 8.3% to 9.3%

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net salesGAAP$6.59B–9.4%
Cost of salesGAAP$2.09B–(4.1)%
Gross profitGAAP$4.50B–17.1%
Gross profit marginGAAP68.3%––
Research, development and engineering expensesGAAP$434M–6.6%
Selling, general and administrative expensesGAAP$2.23B–7.2%
Amortization of intangible assetsGAAP$175M–(6.4)%
Goodwill and other impairmentsGAAP$1M–nm
Total operating expensesGAAP$2.84B–4.1%
Operating incomeGAAP$1.66B–49.1%
Operating income marginGAAP25.2%––
Other income (expense), netGAAP−$95M–(2.1)%
Earnings before income taxesGAAP$1.56B–53.9%
Income taxesGAAP$288M–118.2%
Net earningsGAAP$1.28B–44.3%
Basic earnings per shareGAAP$3.32–43.1%
Diluted earnings per shareGAAP$3.30–44.1%
Weighted-average basic shares outstandingGAAP383.5M––
Weighted-average diluted shares outstandingGAAP386M––
Organic net sales growthnon-GAAP9.0%––
Adjusted gross profit marginnon-GAAP66.0%––
Adjusted operating income marginnon-GAAP27.4%–increased 170 bps
Adjusted net earningsnon-GAAP$1.4B–17.6%
Adjusted net earnings per diluted sharenon-GAAP$3.69–17.9%
Six-month net salesGAAP$12.61B–6.1%
Six-month cost of salesGAAP$4.30B–—
Six-month gross profitGAAP$8.31B–9.5%
Six-month gross profit marginGAAP65.9%––
Six-month research, development and engineering expensesGAAP$847M–4.3%
Six-month selling, general and administrative expensesGAAP$4.51B–3.0%
Six-month amortization of intangible assetsGAAP$355M–0.3%
Six-month goodwill and other impairmentsGAAP$1M–nm
Six-month total operating expensesGAAP$5.71B–1.4%
Six-month operating incomeGAAP$2.60B–33.1%
Six-month operating income marginGAAP20.6%––
Six-month other income (expense), netGAAP−$181M–6.5%
Six-month earnings before income taxesGAAP$2.41B–35.6%
Six-month income taxesGAAP$393M–62.4%
Six-month net earningsGAAP$2.02B–31.4%
Six-month basic earnings per shareGAAP$5.27–30.8%
Six-month diluted earnings per shareGAAP$5.23–31.4%
Six-month weighted-average basic shares outstandingGAAP383.2M––
Six-month weighted-average diluted shares outstandingGAAP386.2M––

Segments

SegmentRevenueq/qy/y
MedSurg and NeurotechnologyOrganic net sales increased 9.2% in the quarter including 9.1% from increased unit volume and 0.1% from higher prices.$3.6B–9.7%
OrthopaedicsOrganic net sales increased 8.6% in the quarter from increased unit volume.$3B–9.1%

full year 2026 outlook

  • Revenueorganic net sales growth in the range of 8.3% to 9.3%
  • Noteadjusted net earnings per diluted share in the range of $14.95 to $15.10
  • Notesales guidance includes a modestly positive pricing impact
  • Noteforeign exchange is expected to have a slightly favorable impact on both sales and adjusted net earnings per diluted share (2) should rates hold near current levels

What drove it

  • Consolidated organic net sales increased 9.0% in the quarter from increased unit volume.
  • MedSurg and Neurotechnology organic net sales increased 9.2%, including 9.1% from increased unit volume and 0.1% from higher prices.
  • Orthopaedics organic net sales increased 8.6% from increased unit volume.
  • Reported gross profit margin was 68.3%, compared with 63.8% in the prior-year quarter.
  • Reported operating income increased 49.1% to $1,659 million.
  • Adjusted operating income margin increased 170 bps to 27.4%.

Concerns

  • The company cited the cybersecurity incident first reported on March 11, 2026 as a risk that could result in breaches, failures or disruptions of information technology systems or products.
  • Reported net earnings include charges for acquisition and integration-related activities, amortization of purchased intangible assets, structural optimization and other special charges, goodwill and other impairments, costs to comply with certain medical device regulations, recall-related matters, regulatory and legal matters and tax matters.
  • The company identified pricing pressures, tariffs and potential trade-policy changes, foreign-currency changes, inflationary pressures, supply-chain disruptions, reimbursement changes and regulatory actions among its risks.
  • Income taxes increased 118.2% to $288 million in the second quarter.

What to watch

  • Delivery against full-year 2026 organic net sales growth guidance of 8.3% to 9.3%.
  • Delivery against full-year 2026 adjusted net earnings per diluted share guidance of $14.95 to $15.10.
  • The expected modestly positive pricing impact included in sales guidance.
  • Whether foreign exchange remains slightly favorable to sales and adjusted net earnings per diluted share should rates hold near current levels.
  • Continued recovery from the cyber incident and the company's execution during the second half of 2026.

Balance sheet and cash flow

  • Cash and cash equivalents were $3,391 million as of June 30, 2026, compared with $4,011 million as of December 31, 2025.
  • Marketable securities were $85 million as of June 30, 2026, compared with $89 million as of December 31, 2025.
  • Inventories were $5,521 million as of June 30, 2026, compared with $5,310 million as of December 31, 2025.
  • Long-term debt, excluding current maturities, was $14,192 million as of June 30, 2026, compared with $14,859 million as of December 31, 2025.
  • Total assets were $47,930 million as of June 30, 2026, compared with $47,844 million as of December 31, 2025.
  • Shareholders' equity was $23,988 million as of June 30, 2026, compared with $22,420 million as of December 31, 2025.
  • Six-month net earnings in operating activities were $2,021 million, compared with $1,538 million.
  • Six-month depreciation was $241 million, compared with $214 million.

Analysis

Stryker reported a strong second quarter, with GAAP net sales of $6,589 million, up 9.4%, and organic net sales growth of 9.0%. The company attributed consolidated organic growth to increased unit volume. Both operating segments contributed: MedSurg and Neurotechnology delivered 9.7% reported sales growth and 9.2% organic growth, while Orthopaedics delivered 9.1% reported sales growth and 8.6% organic growth. Management said it made significant progress in recovery from the cyber incident and entered the second half with regained momentum.

Profit growth exceeded sales growth in the quarter. Gross profit increased 17.1% to $4,498 million, and GAAP gross profit margin was 68.3%, compared with 63.8% in the prior-year quarter. Operating income increased 49.1% to $1,659 million, while GAAP operating income margin was 25.2%, compared with 18.5%. Adjusted operating income margin increased 170 bps to 27.4%, and adjusted gross profit margin was 66.0%.

GAAP net earnings increased 44.3% to $1,276 million and diluted EPS increased 44.1% to $3.30. On a non-GAAP basis, adjusted net earnings were $1.4 billion, up 17.6%, and adjusted diluted EPS was $3.69, up 17.9%. The filing identifies several items excluded from adjusted results, including acquisition and integration-related activities, purchased-intangible amortization, structural optimization and other special charges, impairments, regulatory and legal matters, and tax matters.

The six-month results also showed improved profitability. Net sales increased 6.1% to $12,609 million, operating income increased 33.1% to $2,595 million, and net earnings increased 31.4% to $2,021 million. Six-month gross profit margin was 65.9%, compared with 63.8%, and operating income margin was 20.6%, compared with 16.4%.

Stryker narrowed its full-year 2026 outlook to organic net sales growth of 8.3% to 9.3% and adjusted net earnings per diluted share of $14.95 to $15.10. The guidance includes a modestly positive pricing impact, while foreign exchange is expected to have a slightly favorable impact on sales and adjusted EPS if rates remain near current levels. Cash and cash equivalents were $3,391 million at June 30, 2026, versus $4,011 million at December 31, 2025, and long-term debt excluding current maturities was $14,192 million versus $14,859 million.

Management, verbatim

We made significant progress in our recovery from the cyber incident, delivering strong growth in sales, earnings per share and operating cash flow in the second quarter.

Kevin A. Lobo, Chair and CEO

With our steady cadence of innovation and disciplined operational execution, we enter the second half of 2026 with regained momentum and remain confident in our ability to grow at the high end of MedTech.

Kevin A. Lobo, Chair and CEO

Not in the filing

stated, not guessed
  • Previous-release outlook was not provided, so comparison with prior guidance is unavailable.
  • Quarterly operating cash flow was not provided.
  • Quarterly free cash flow was not provided.
  • The filing text provided only a partial six-month cash flow statement, ending after depreciation; complete operating cash flow, investing cash flow, financing cash flow and free cash flow figures were not provided.
  • Share repurchases were not provided.
  • Dividend declarations or payments were not provided.
  • Adjusted operating income amount was not provided.
  • Adjusted gross profit amount was not provided.
  • Prior-year adjusted gross profit margin was not provided.
  • Prior-year adjusted operating income margin was not provided as a percentage.
  • Prior-year adjusted net earnings amount was not provided.
  • Prior-year adjusted diluted EPS amount was not provided.
  • Sequential segment revenue comparisons were not provided.
  • Full-year 2026 gross-margin, operating-expense and tax-rate guidance was not provided.
  • GAAP full-year 2026 net sales growth and GAAP diluted EPS guidance were not provided.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about SYK earnings dates

When is Stryker's next earnings date?
AlphAI has no date for SYK yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.